Literature DB >> 33686211

Prognostic significance of hypertension at the onset of lupus nephritis in Chinese patients: prevalence and clinical outcomes.

Rong Rong1,2,3,4, Qiong Wen1,2,3, Yating Wang1,2,3, Qian Zhou5, Yagui Qiu1,2,3, Miaoqing Lu1,2,3, Xiaotian Liu1,2,3, Wei Chen6,7,8, Xueqing Yu1,2,3.   

Abstract

The demographic features, and clinical and histological characteristics of lupus nephritis (LN) patients with hypertension in the Chinese population remain unclear. Hence, the clinical characteristics of LN with and without hypertension were retrospectively analyzed. A total of 764 LN patients (53.1%) were hypertensive. These hypertensive patients had higher levels of serum creatinine and blood urea nitrogen, and lower estimated glomerular filtration rates, when compared to their normotensive counterparts (P < 0.05). Furthermore, these hypertensive patients had higher median acuity index and chronicity index scores, when compared to normotensives (P < 0.001). In terms of histology, hypertensive patients were more likely to develop glomerular sclerosis, thickened glomerular capillary loops, or crescent formations, and had more severe endothelial cell proliferation, when compared to normotensive patients (P < 0.001). Hypertensive patients also had a higher percentage for more severe tubular atrophy, interstitial inflammatory cell infiltration and interstitial fibrosis (P < 0.001). Compared with normotensive patients, hypertensive patients exhibited a significant decline in survival time and rate for all end points (P < 0.01). The presence of hypertension was an independent predictor of mortality (P = 0.009), ESRD (P = 0.026), and doubling of serum creatinine (P = 0.017). In conclusion, hypertension is associated with poor clinical and renal outcome in LN patients. The monitoring and control of hypertension should be considered an important clinical goal in the treatment of LN patients.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.

Entities:  

Mesh:

Year:  2021        PMID: 33686211     DOI: 10.1038/s41371-021-00492-w

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

1.  Manifestations of systemic lupus erythematosus.

Authors:  Manole Cojocaru; Inimioara Mihaela Cojocaru; Isabela Silosi; Camelia Doina Vrabie
Journal:  Maedica (Buchar)       Date:  2011-10

2.  Poor prognostic factors of lupus nephritis.

Authors:  Khawla Kammoun; Faigal Jarraya; Lamia Bouhamed; Mahmoud Kharrat; Saloua Makni; Mohamed Ben Hmida; Hafedh Makni; Neila Kaddour; Tahia Boudawara; Zouhir Bahloul; Jamil Hachicha
Journal:  Saudi J Kidney Dis Transpl       Date:  2011-07

Review 3.  Assessment of systemic lupus erythematosus.

Authors:  G K W Lam; M Petri
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

4.  Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure.

Authors:  Mikkel Faurschou; Henrik Starklint; Poul Halberg; Søren Jacobsen
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

5.  Lupus nephritis: histopathologic features, classification and histologic scoring in renal biopsy.

Authors:  Jovan Dimitrijević; Ljubica Dukanović; Zoran Kovacević; Radovan Bogdanović; Doko Maksić; Rajko Hrvacević; Anastasija Aleksić; Radomir Naumović; Dijana Jovanović; Goran Brajusković; Ivica Milosavljević
Journal:  Vojnosanit Pregl       Date:  2002 Nov-Dec       Impact factor: 0.168

6.  Lupus nephritis: an overview of recent findings.

Authors:  Alberto de Zubiria Salgado; Catalina Herrera-Diaz
Journal:  Autoimmune Dis       Date:  2012-03-22

7.  The outcome of patients with lupus nephritis and the impact of cardiovascular risk factors.

Authors:  O Drakoulogkona; A L Barbulescu; I Rica; A E Musetescu; P L Ciurea
Journal:  Curr Health Sci J       Date:  2011-06-23
  7 in total
  1 in total

Review 1.  Treatment of Lupus Nephritis from Iranian Traditional Medicine and Modern Medicine Points of View: A Comparative Study.

Authors:  Yasaman Vahedi-Mazdabadi; Mina Saeedi
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-09       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.